Nayan Gregory Parekh takes up role as current ceo becomes executive chairman
Biocartis, a Swiss developer of compact molecular diagnostic (MDx) systems, has appointed Dr Nayan Gregory Parekh as its new chief executive.
Parekh brings to Biocartis a wealth of pharmaceutical and biotechnology industry experience and has been an executive director of the Board since April 2011.
Rudi Pauwels, co-founder of Biocartis and current ceo, will become executive chairman and = concentrate on the company’s scientific and technology strategy.
Parekh has held senior management positions at Novartis and Deutsche Bank and has a broad network of relationships and experience across a number of healthcare fields and geographies.
Most recently, he was at New Rhein Healthcare, a healthcare investment firm where he was one of the founding partners. Before setting up New Rhein, he spent six years as head of corporate development at Novartis.
Prior to joining Novartis in 2004, Parekh spent ten years in investment banking, primarily focusing on the pharmaceutical and biotechnology sectors.